Health
Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds – News-Medical.Net – Burnie Online News
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
Continue Reading
-
Noosa News11 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News19 hours agoCountdown on for Noosa Eat & Drink Festival 2025
-
Noosa News16 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Business17 hours ago5 things to watch on the ASX 200 on Wednesday 21 May 2025